MitoQ to Improve Vascular Funciton in Preeclampsia
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia…
Conditions studied
Preeclampsia, Pregnancy
About this study
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.
Interventions
- Dietary Supplement: Mitoquinol Mesylate — Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
- Other: Placebo — Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.
Primary outcomes
- Brachial Artery Flow Mediated Dilation (FMD) (1-2 times per week from enrollment until delivery, up to 10 months)
Eligibility information
Study locations
- Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.